Intravitreal bevacizumab (Avastin) and panretinal photocoagulation in the treatment of high-risk proliferative diabetic retinopathy

Journal of Ocular Pharmacology and Therapeutics

Volumn 29, Issue 6, 2013, Pages 550-555

  Yang, Chang Sue ^a,b,c   Hung, Kuo Che ^a,b   Huang, Yi Ming ^a,b   Hsu, Wen Ming ^c,d  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^d Shuang Ho Hospital   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BEVACIZUMAB; CORTICOSTEROID;

ADULT; AGED; ARTICLE; CASE STUDY; CLINICAL ARTICLE; CLINICAL EVALUATION; DIABETES MELLITUS; DIABETIC RETINOPATHY; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HIGH RISK PATIENT; HUMAN; INTERVENTION STUDY; INTRAOCULAR PRESSURE; LASER COAGULATION; MALE; PANRETINAL LASER PHOTOCOAGULATION; PROSPECTIVE STUDY; RETINA DETACHMENT; RETINA NEOVASCULARIZATION; SLIT LAMP; TREATMENT DURATION; VISUAL ACUITY; VISUAL ACUITY CHART; VITRECTOMY; VITREOUS BODY; VITREOUS HEMORRHAGE;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; COMBINED MODALITY THERAPY; DIABETIC RETINOPATHY; FEMALE; HUMANS; INTRAVITREAL INJECTIONS; LIGHT COAGULATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RETINAL NEOVASCULARIZATION; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VITREOUS HEMORRHAGE;

EID: 84880201329     PISSN: 10807683     EISSN: 15577732     Source Type: Journal    
DOI: 10.1089/jop.2012.0202     Document Type: Article

References (23)

1. Klein, R. Retinopathy in a population-based study. Trans. Am. Ophthalmol. Soc. 90:561-594, 1992
2. Chew, E.Y. Major clinical trials of vitreoretinal diseases. In: Regillo, C.D., Brown, G.C., Flyn, H.W., eds. Vitreoretinal Disease, the Essentials. New York: Theme Medical Publishers, Inc.; 1999; p. 667-677.
3. Early Treatment Diabetic Retinopathy Study Research Group. Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS Report No. 12. Ophthalmology. 98:823-833,1991
4. Adamis, A.P., Miller, J.W., Bernal, M.T., et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am. J. Ophthalmol. 118:445-450, 1994
5. Aiello, L.P., Avery, R.L., Arrigg, P.G, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N. Engl. J. Med. 331:1480-1487, 1994
6. Pe'er, J., Shweiki D., Itin, A., et al. Hypoxia-induced expression of vascular endothelial growth factor by retinal cells is a common factor in neovascularizing ocular diseases. Lab. Invest. 72:638-645, 1995
7. Noma, H., Funatsu, H., Yamasaki, M., et al. Pathogenesis of macular edema with branch retinal vein occlusion and intraocular levels of vascular endothelial growth factor and interleukin-6. Am. J. Ophthalmol. 140:256-261, 2005
8. Malik, R.A., Li, C., Aziz, W., et al. Elevated plasma CD105 and vitreous VEGF levels in diabetic retinopathy. J. Cell. Mol. Med. 9:692-697, 2005
9. Manzano, R.P.A., Peyman, G.A., Khan, P., et al. Testing intravitreal toxicity of bevacizumab (Avastin). Retina. 26:257- 261, 2006
10. Spaide, R.F., and Fisher, Y.L. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina. 26:275-278, 2006
11. Avery, R.L., Pearlsman, J., Pieramici, D.J., et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology. 113:1695-1705, 2006
12. Jorge, R., Costa, R.A., Calucci, D., et al. Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE Study). Retina. 26:1006-1013, 2006
13. Diabetic Retinopathy Study Research Group. Four risk factors for severe visual loss in diabetic retinopathy. The third report from the Diabetic Retinopathy Study. Arch. Ophthalmol. 97:654-655, 1979
14. Tolentino, M.J., Miller, J.W., Gragoudas, E.S., et al. Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. Ophthalmology. 103:1820-1828, 1996
15. Early Treatment Diabetic Retinopathy Study Research Group. Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Ophthalmology. 98:766-785, 1991
16. Vander, J.F., Duker, J.S., Benson, W.E., et al. Longterm stability and visual out-come after favourable initial response of proliferative diabetic retinopathy to panretinal photocoagulation. Ophthalmology. 98:1575-1579, 1991
17. Flynn, H.W., Jr, Chew, E.Y., Simons, B.D., et al. Pars plana vitrectomy in the Early Treatment Diabetic Retinopathy Study. ETDRS Report No. 17. Ophthalmology. 99:1351-1357, 1992
18. Doft, B.H., and Blankenship,G.W. Single vsmultiple treatment sessions of argon laser panretinal photocoagulation for proliferative diabetic retinopathy. Ophthalmology. 89:772-779, 1982
19. Matsumoto, Y., Freund, K.B., Peiretti, E., et al. Rebound macular edema following bevacizumab (Avastin) therapy for retinal venous occlusive disease. Retina. 27:426-431, 2007
20. Arevalo, J.F., Wu, L., Sanchez, J.G., et al. Intravitreal bevacizumab (Avastin) for proliferative diabetic retinopathy: 6-months follow-up. Eye. 23:117-123, 2009
21. Wu, L., Arevalo, J.F., Roca, J.A., et al. Comparison of two doses of intravitreal bevacizumab (Avastin) for treatment of macular edema secondary to branch retinal vein occlusion: results from the Pan-American Collaborative Retina Study Group at 6 months of follow-up. Retina. 28:212-219, 2008
22. Huang, Y.H., Yeh, P.T., Chen, M.S., Yang, C.H., and Yang, C.M. Intravitreal bevacizumab and panretinal photocoagulation for proliferative diabetic retinopathy associated with vitreous hemorrhage. Retina. 29:1134-1140,2009
23. Arevalo, J.F., Maia, M., Flynn, H.W., Jr., et al. Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy. Br. J. Ophthalmol. 92:213-216,2008